ArticleBMC cancer2025

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE).

Hidekazu Hirano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.